|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.42 USD | -1.03% |
|
+0.46% | +15.35% |
| 09/04 | Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says | MT |
| 09/04 | Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards | DJ |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 129.26 | +6.46% | 27 | ||||||
| 1,209.69 | +28.76% | 29 | ||||||
| 241.92 | +1.45% | 24 | ||||||
| 249.03 | +19.76% | 29 | ||||||
| 220.27 | +7.36% | 21 | ||||||
| 153.86 | -0.37% | 21 | ||||||
| 351.69 | +0.19% | 29 | ||||||
| 157.86 | +13.57% | 28 | ||||||
| 309.77 | +28.72% | 22 | ||||||
| 63.04 | +7.54% | 25 | ||||||
| 20.44 | -6.08% | 20 | ||||||
| 96.1 | +19.84% | 23 | ||||||
| 548.45 | +25.71% | 29 | ||||||
| 9,783.33 | +12.78% | 15 | ||||||
| 6,003.53 | +4.74% | 15 | ||||||
| 80.33 | +40.78% | 17 | ||||||
| 46.53 | +15.97% | 19 | ||||||
| 4.27 | +17.28% | 16 | ||||||
| Average | 1,092.74 | +13.58% | 23 | ||||||
| Weighted average by Cap. | 717.66 | +13.60% | 25 |
- Stock Market
- Equities
- MRK Stock
- Sector Merck & Co., Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition